Mabpharm (HKG:2181) said its core product, CMAB008 (infliximab for injection), has received approval from the Drug Regulatory Authority of Pakistan, according to its filing on Thursday.
This approval covers treatments for ulcerative colitis, ankylosing spondylitis, rheumatoid arthritis, Crohn's disease, fistula Crohn's disease, and psoriasis.
CMAB008 is the first infliximab developed in China and approved for marketing. The drug, manufactured by Taizhou Mabtech Pharmaceutical, is available in a 100mg/vial injection form.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.